rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    APVO
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Aptevo Therapeutics Announces Exercise of Existing Warrants for $3.0 Million Gross Proceeds
      Nov 11Yahoo FinanceAPVO
      Aptevo Presents Preclinical Data at SITC 2026 Showing Potential to Overcome Immune Suppression in Solid Tumors
      Nov 9Yahoo FinanceAPVO
      Aptevo Achieves Key Clinical Development Objective, Significantly Reducing Infusion-Related Reactions with Mipletamig in Frontline AML
      Nov 5Yahoo FinanceAPVO
      Aptevo Therapeutics files prospectus supplement for up to $2.3 million stock offering
      Nov 2Investing.comAPVO
      Aptevo Reports Mipletamig Combination Therapy Enabled 21% of Frontline AML Patients to Advance to Potentially Curative Stem Cell Transplant
      Oct 26Yahoo FinanceAPVO
      Aptevo to Showcase Multispecific Platform at SITC 2026 Annual Meeting
      Oct 14Yahoo FinanceAPVO
      Aptevo advances trispecific cancer therapy manufacturing
      Sep 24Investing.comAPVO
      Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development

      Company Making Critical Progress in Scalable Manufacturing and Preparing the Lead Trispecific Candidate for Future Human TestingTrispecifics Combine Three Complementary Cancer-Fighting Functions in One Molecule, Enabling a Coordinated Approach to Recognizing Cancer, Activating Immune Cells and Addressing Tumor DefensesSEATTLE, WA / ACCESS Newswire / September 24, 2026 / Inc. ("Aptevo" or the "Company") (Nasdaq:APVO), a clinical-stage biotechnology company developing novel multispecific immuno-on

      Sep 24Yahoo FinanceAPVO
      Aptevo Therapeutics Reports 93% Clinical Benefit Rate in Key Leukemia Trial
      Sep 3BenzingaAPVO
      Aptevo Reports 93% Clinical Benefit Rate for Mipletamig Triplet in TP53-Mutated AML
      Sep 3Yahoo FinanceAPVO
      Why is Aptevo Therapeutics stock slumping today?
      Sep 3Investing.comAPVO
      Aptevo reports 93% clinical benefit rate in AML trial subset
      Sep 3Investing.comAPVO
      Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML
      Sep 3Yahoo FinanceAPVO
      APVO: Focusing on Three Key Areas of Development
      Aug 24Yahoo FinanceAPVO

      This is the newest page. Registered accounts read further back.